TRIAP1 and cancer: In TCGA data, high expression of TRIAP1 was a high‐risk factor for cancer patient survival, and it was significantly associated with poorer OS in 7 tumors and poorer disease‐specific survival (DSS) in eight tumors (hazard ratio (HR) > 1 and p < 0.05).